PMID- 36039462
OWN - NLM
STAT- MEDLINE
DCOM- 20220831
LR  - 20220831
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 42
IP  - 9
DP  - 2022 Sep
TI  - Neuroectodermal Rosettes in Immature Teratomas Are Not the Counterpart of 
      Embryonal Tumours With Multilayered Rosettes.
PG  - 4337-4344
LID - 10.21873/anticanres.15934 [doi]
AB  - BACKGROUND/AIM: Immature teratomas (IMT) are malignant germ cell tumours composed 
      of immature embryonal tissue, mostly neuroectodermal tubules and rosettes. 
      Meanwhile, embryonal tumours with multilayered rosettes (ETMR) are aggressive 
      central nervous system tumours composed of neurocyte proliferation with rosette 
      formation. The histopathological appearance of rosette formation in ETMR is the 
      same as that in IMT. Recently, 19q13.42 amplification was reported as a specific 
      genetic marker of ETMR. The aim of this study was to compare ETMR with IMT from 
      histological, immunohistochemical and genetic perspectives. MATERIALS AND 
      METHODS: We retrospectively analysed tumour samples from 48 patients with IMT and 
      1 patient with ETMR. We performed fluorescence in situ hybridization (FISH) 
      analysis, which revealed amplification of the 19q13.42 locus in the ETMR case. In 
      addition, immunohistochemical analyses of LIN28A, beta-catenin and p53 were 
      performed. RESULTS: In FISH analysis all 48 cases of IMT showed diploidy. By 
      immunohistochemical analysis, LIN28A expression was observed in 54% of IMT cases 
      (25/48 cases) and in the ETMR case. Nuclear staining of beta-catenin was observed in 
      33% of IMT cases (16/48 cases). Meanwhile, aberrant expression of p53 was not 
      identified in IMT nor ETMR cases. CONCLUSION: Genetic changes associated with IMT 
      differ from those in ETMR, but LIN28A protein immunohistochemical expression, 
      which is specific for ETMR, can be a biomarker for the immature neuroepithelial 
      component in IMT.
CI  - Copyright (c) 2022 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Magarifuchi, Naomi
AU  - Magarifuchi N
AD  - Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Yamada, Yuichi
AU  - Yamada Y
AD  - Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Oishi, Yoshihiro
AU  - Oishi Y
AD  - Department of Pathology, Izuka Hospital, Fukuoka, Japan.
FAU - Kato, Kiyoko
AU  - Kato K
AD  - Department of Gynaecology and Obstetrics, Graduate School of Medical Sciences, 
      Kyushu University, Fukuoka, Japan.
FAU - Taguchi, Kenichi
AU  - Taguchi K
AD  - Department of Pathology, National Hospital Organization Kyushu Cancer Center, 
      Fukuoka, Japan.
FAU - Oda, Yoshinao
AU  - Oda Y
AD  - Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan; oda.yoshinao.389@m.kyushu-u.ac.jp.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (beta Catenin)
SB  - IM
MH  - *Brain Neoplasms/pathology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Neoplasms, Germ Cell and Embryonal/genetics
MH  - *Neuroectodermal Tumors, Primitive/genetics/pathology
MH  - Retrospective Studies
MH  - *Teratoma/genetics
MH  - beta Catenin/genetics
OTO - NOTNLM
OT  - C19MC
OT  - ETMR
OT  - LIN28A
OT  - Neuroepithelium
OT  - immature teratoma
EDAT- 2022/08/31 06:00
MHDA- 2022/09/01 06:00
CRDT- 2022/08/30 02:13
PHST- 2022/06/01 00:00 [received]
PHST- 2022/06/29 00:00 [revised]
PHST- 2022/07/08 00:00 [accepted]
PHST- 2022/08/30 02:13 [entrez]
PHST- 2022/08/31 06:00 [pubmed]
PHST- 2022/09/01 06:00 [medline]
AID - 42/9/4337 [pii]
AID - 10.21873/anticanres.15934 [doi]
PST - ppublish
SO  - Anticancer Res. 2022 Sep;42(9):4337-4344. doi: 10.21873/anticanres.15934.